Abstract 271P
Background
Histone modifications are important for tissue homeostasis, and their mutations are involved in carcinogenesis. Mutations in a histone modifier, UTX (also known as KDM6A), and loss of its counterpart UTY (also known as KDM6C) are common in prostate cancer (PCa). However, mechanisms of carcinoma development and drug sensitivity in UTX-deficient PCa are not clear. We hypothesized that elucidating the mechanism of carcinogenesis by loss of UTX may develop novel molecular targeted therapies for UTX-deficient PCa.
Methods
We generated genetically-engineered mice with deletion of both Utx and Uty in the prostate tissue (UtxΔ, UtyΔ) and crossed with mice with a heterozygous deletion of p53 (p53+/−) to create UtxΔ, UtyΔ and p53+/− compound mice. Mice were administered a high-fat diet (HFD) starting at 8 weeks of age to promote cancer growth by inflammation. We found the development of PCa with Gleason score (GS) = 3+3 at 4 months after HFD treatment. Isolated prostate tissues were subjected to pathologic, molecular, and cellular analyses. RM-2 mouse PCa cells which do not express UTY were knocked down for Utx (siUtx) and control (siNC) by siRNAs to assess changes in the abilities of proliferation and migration.
Results
RM-2 siUtx cells showed increased proliferation and migration abilities compared with RM-2 siNC cells. By performing high-throughput RNA sequencing (RNA seq) and gene set enrichment analysis (GSEA) using mouse prostate tissues, we found that loss of UTX inactivated a pathway for DNA damage repair such as ATM pathway. To confirm this, we irradiated Utx+, UtyΔ, p53+/− mice and UtxΔ, UtyΔ, p53+/− mice and found that the time required for DNA damage repair was prolonged in UtxΔ, UtyΔ, p53+/− mice compared with Utx+, UtyΔ, p53+/− mice by immunofluorescent staining with an antibody against γH2AX, a marker of DNA repair. We also found that olaparib inhibited proliferation with RM-2 siUtxcells compared with RM-2 siNC cells.
Conclusions
Inactivation of the DNA damage repair pathway was suggested as one of the oncogenic mechanisms of UTX-deficient PCa. Moreover, olaparib may be effective in the treatment of PCa with loss of UTX function. Since loss of UTX function has also been observed in other types cancers, our therapeutic strategy may apply for other UTX-deficient cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract